Increased macroH2A1.1 expression correlates with poor survival of triple-negative breast cancer patients.

Código QR

Increased macroH2A1.1 expression correlates with poor survival of triple-negative breast cancer patients.

<h4>Purpose</h4>Epithelial-Mesenchymal Transition (EMT) features appear to be key events in development and progression of breast cancer. Epigenetic modifications contribute to the establishment and maintenance of cancer subclasses, as well as to the EMT process. Whether histone variants...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anne-Claire Lavigne, Magali Castells, Jérôme Mermet, Silvia Kocanova, Mathieu Dalvai, Kerstin Bystricky
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6fa91084ceb34bd88caa64b2c2e53c08
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Activation of p21 by HDAC inhibitors requires acetylation of H2A.Z.
por: Luca Bellucci, et al.
Publicado: (2013)

Cell cycle and anti-estrogen effects synergize to regulate cell proliferation and ER target gene expression.
por: Mathieu Dalvai, et al.
Publicado: (2010)

Immunopositivity for histone macroH2A1 isoforms marks steatosis-associated hepatocellular carcinoma.
por: Francesca Rappa, et al.
Publicado: (2013)

LSH mediates gene repression through macroH2A deposition
por: Kai Ni, et al.
Publicado: (2020)

CDK5-dependent phosphorylation and nuclear translocation of TRIM59 promotes macroH2A1 ubiquitination and tumorigenicity
por: Youzhou Sang, et al.
Publicado: (2019)

MacroH2A1 chromatin specification requires its docking domain and acetylation of H2B lysine 20
por: Penelope D. Ruiz, et al.
Publicado: (2018)

The epigenetic regulator LSH maintains fork protection and genomic stability via MacroH2A deposition and RAD51 filament formation
por: Xiaoping Xu, et al.
Publicado: (2021)

RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis
por: Zhuming Yin, et al.
Publicado: (2021)

GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
por: Qin Wu, et al.
Publicado: (2020)

Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer
por: Anna E. M. Bastiaansen, et al.
Publicado: (2020)

Co-dependency for MET and FGFR1 in basal triple-negative breast cancers
por: Vanessa Y. C. Sung, et al.
Publicado: (2021)

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
por: Dominik Glodzik, et al.
Publicado: (2020)

NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation
por: Kai Miao, et al.
Publicado: (2020)

TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
por: Virginie Maire, et al.
Publicado: (2013)

NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer
por: Ge Qin, et al.
Publicado: (2020)

Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer.
por: Katsuhiro Yoshikawa, et al.
Publicado: (2021)

Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers
por: Al-saraireh YM, et al.
Publicado: (2021)

Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells
por: Swanner J, et al.
Publicado: (2015)

A triple negative breast cancer: what it is not!
por: Katakkar SB
Publicado: (2012)

Triple negative breast cancer: an Indian perspective
por: Akhtar M, et al.
Publicado: (2015)

Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas.
por: Wen-Hung Kuo, et al.
Publicado: (2012)

A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
por: Miyuki Kitahara, et al.
Publicado: (2021)

TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis
por: Oihana Iriondo, et al.
Publicado: (2018)

Signaling of MK2 sustains robust AP1 activity for triple negative breast cancer tumorigenesis through direct phosphorylation of JAB1
por: Haoming Chen, et al.
Publicado: (2021)

Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
por: Aurelia Noske, et al.
Publicado: (2021)

BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression
por: Yu Li, et al.
Publicado: (2021)

BRCA2 mutations and triple-negative breast cancer.
por: Peter Meyer, et al.
Publicado: (2012)

Triple-negative breast cancer: treatment challenges and solutions
por: Collignon J, et al.
Publicado: (2016)

Opportunities for metastatic triple negative breast cancer therapy
por: Inna P. Ganshina, et al.
Publicado: (2021)

Antiangiogenic therapy for breast cancer with triple negative phenotype
por: Inna P. Ganshina, et al.
Publicado: (2021)

Palmatine sensitizes chemoresistant triple negative breast cancer cells via efflux inhibition of multidrug resistant protein 1.
por: Selase Ativui, et al.
Publicado: (2021)

Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer
por: Asmus Heumann, et al.
Publicado: (2017)

Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer
por: Paolo Peterlongo, et al.
Publicado: (2021)

Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer
por: Leilei Fu, et al.
Publicado: (2016)

MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer
por: Kwok-Kin Wong, et al.
Publicado: (2021)

Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
por: Marina K. Ibragimova, et al.
Publicado: (2021)

Molecular heterogeneity in adjacent cells in triple-negative breast cancer
por: Huebschman ML, et al.
Publicado: (2015)

Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel–cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines
por: Ye J, et al.
Publicado: (2016)

Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer
por: Xin Zheng, et al.
Publicado: (2021)

Hsa-mir-3163 and CCNB1 may be potential biomarkers and therapeutic targets for androgen receptor positive triple-negative breast cancer.
por: Pengjun Qiu, et al.
Publicado: (2021)